Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy

Authors

Rui Li, Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China.
Yuhao Hao, Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China.
Kyle Roche, School of Medicine and Health Sciences, The George Washington University, Washington, DC 20052, USA.
Guiyuan Chen, Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China.
Wen Pan, Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China.
Andrew Z. Wang, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Yuanzeng Min, Department of Chemistry, University of Science and Technology of China, Hefei, 230026, China; Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Hefei, 230026, China; CAS Key Lab of Soft Matter Chemistry, University of Science and Technology of China, Hefei, 230026, China. Electronic address: minyz@ustc.edu.cn.

Document Type

Journal Article

Publication Date

10-1-2023

Journal

Biomaterials

Volume

301

DOI

10.1016/j.biomaterials.2023.122290

Keywords

Anti-PD-1; Chemoimmunotherapy; Damage associated molecular patterns; Nanovaccines; Neoantigens

Abstract

Several chemoimmunotherapies have been approved by the FDA for the treatment of various cancers. Chemotherapy has the potential to improve the efficacy of immunotherapy by inducing immunogenic cell death (ICD) of tumor cells, promoting the release of tumor associated antigens (TAAs), tumor specific antigens (TSAs) and damage associated molecular patterns (DAMPs), and disrupting immunosuppressive microenvironments by tumor debulking. Unfortunately, systemic administration of chemotherapeutics carries side effects of blunting anti-cancer immune response through systemic immunosuppression, which deserves to be explored as an inner contradiction in chemoimmunotherapy. Here, we proposed the hypothesis of "immunogenicity equivalence" in chemoimmunotherapy that chemotherapeutics-induced immunogenic antigens and DAMPs in vitro that can subsequently be incorporated into nanovaccines, which will possess comparable immunostimulatory potential when compared to tumors treated with systemic chemotherapy in vivo. The proteomic analysis confirmed that our nanovaccines contained TAAs, TSAs and DAMPs. Improvement in treatment outcomes in tumor-bearing mice receiving anti-PD-1 and chemotherapy-induced nanovaccines was then observed. Furthermore, we demonstrated the feasibility of replacing long-term chemotherapy with nanovaccines in chemoimmunotherapy. Our nanovaccine strategy would be a general choice for formulating cancer vaccines in personalized medicine.

APA Citation

Li, Rui; Hao, Yuhao; Roche, Kyle; Chen, Guiyuan; Pan, Wen; Wang, Andrew Z.; and Min, Yuanzeng, "Chemotherapy-induced nanovaccines implement immunogenicity equivalence for improving cancer chemoimmunotherapy" (2023). GW Authored Works. Paper 3184.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/3184

Department

School of Medicine and Health Sciences Resident Works